SUBCUTANEOUS ADMINISTRATION OF RECOMBINANT GLYCOSYLATED INTERLEUKIN 6 IN PATIENTS WITH CANCER: PHARMACOKINETICS, PHARMACODYNAMICS AND IMMUNOMODULATORY EFFECTS

This publication has 32 references indexed in Scilit:

• Phase I study of interleukin-6 in children with solid tumours in relapse
  European Journal Of Cancer, 1997
• A complex of the soluble interleukin‐6 receptor and interleukin‐6 is internalized via the signal transducer gp130
  FEBS Letters, 1996
• Immunomodulatory and Hematopoietic Effects of Recombinant Human Interleukin-6 in Patients with Advanced Renal Cell Cancer
  Journal of Interferon & Cytokine Research, 1996
• Hematologic and Immunologic Evaluation of Recombinant Human Interleukin-6 in Patients with Advanced Malignant Disease: Evidence for Monocyte Activation
  Journal of Immunotherapy, 1996
• The acute phase protein response in patients receiving subcutaneous IL-6
  Clinical and Experimental Immunology, 1995
• A Phase II Study of the Continuous Intravenous Infusion of Interleukin-6 for Metastatic Renal Cell Carcinoma
  Journal of Immunotherapy, 1995
• Tumour stimulating effects of recombinant human interleukin-6
  The Lancet, 1994
• A Phase I Trial of Intravenous Interleukin-6 in Patients with Advanced Cancer
  Journal of Immunotherapy, 1994
• Comparative pharmacokinetics of single‐dose administration of mammalian and bacterially‐derived recombinant human granulocyte‐macrophage colony‐stimulating factor
  European Journal of Haematology, 1993
• High amounts of circulating interleukin (IL)‐6 in the form of monomeric immune complexes during anti‐IL‐6 therapy. Towards a new methodology for measuring overall cytokine production in human in vivo
  European Journal of Immunology, 1992